Specify a stock or a cryptocurrency in the search bar to get a summary
Cardiol Therapeutics Inc Class A
CRDLCardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada. Address: 2265 Upper Middle Road East, Oakville, ON, Canada, L6H 0G5
Analytics
WallStreet Target Price
13.71 CADP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures CRDL
Dividend Analytics CRDL
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CRDL
Stock Valuation CRDL
Financials CRDL
Results | 2019 | Dynamics |